Have any questions? 706-721-6582 or cts@augusta.edu
- (Oxbryta) An Open-label, Expanded Access Protocol for Pediatric Patients with Sickle Cell Disease Who Have No Alternative Treatment Options
Clinical Trial
(Oxbryta) An Open-label, Expanded Access Protocol for Pediatric Patients with Sickle Cell Disease Who Have No Alternative Treatment Options
The purpose of this Expanded Access Program (EAP) is to give children 4-11 years old an experimental drug treatment for their sickle cell disease. This drug will be part of their normal, routine care. It is being made available to patients who have no other treatment options.
Eligibility Criteria
- 1. Documented diagnosis of Sickle Cell Disease of any genotype 2. Ineligible or unable to participate in actively recruiting clinical studies of voxelotor 3. Baseline hemoglobin less than or equal to 10.5 g/dl 4. No alternative treatment options in the judgement of the treating investigator 5. Able to participate safely and comp;y with requirements of this EAP program
RESEARCH. INNOVATION. DISCOVERY.